Drug Trial Radar · NCT05052996
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
142
Actual
Start
Oct 5, 2021
Primary completion
Dec 19, 2023
Study completion Mar 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24.
Conditions
- HIV-1 Infection
Interventions
ISLDrug
Capsules administered orally without regard to food
LENDrug
Tablets administered orally without regard to food
B/F/TAFDrug
Tablets administered orally without regard to food
ISL/LEN FDCDrug
Tablets administered orally without regard to food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot AlgorithmTime frame: Week 24
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Pacific Oaks Medical Group
Beverly Hills, California
Ruane Clinical Research Group, Inc
Los Angeles, California
Mills Clinical Research
Los Angeles, California
Hoag Medical Group - Newport Beach
Newport Beach, California
BIOS Clinical Research
Palm Springs, California
Optimus Medical Group
San Francisco, California
Public Health Institute at Denver Health
Denver, Colorado
Vivent Health
Denver, Colorado
Washington Health Institute
Washington D.C., District of Columbia
The George Washington University Medical Faculty Associates Inc.
Washington D.C., District of Columbia
CAN Community Health Care, Inc.
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
JEM Research Institute
Lake Worth, Florida
Schiff Center for Liver Diseases/University of Miami
Miami, Florida
Floridian Clinical Research
Miami Lakes, Florida
Orlando Immunology Center
Orlando, Florida
Emory University Hospital Midtown Infectious Disease Clinic
Atlanta, Georgia
Atlanta ID Group, PC
Atlanta, Georgia
Metro Infectious Disease Consultants
Decatur, Georgia
Chatham County Health Department
Savannah, Georgia
John A. Burns School of Medicine, University of Hawaii Clinics at Kaka'ako
Honolulu, Hawaii
Howard Brown Health Center
Chicago, Illinois
Northstar Healthcare
Chicago, Illinois
Indiana CTSI Clinical Research Center
Indianapolis, Indiana
Boston Medical Center
Boston, Massachusetts
AccessHealth MA
Boston, Massachusetts
Be Well Medical Center
Berkley, Michigan
Hennepin Healthcare HCMC
New Brighton, Minnesota
Southampton Healthcare, Inc.
St Louis, Missouri
Huntridge Family Clinic
Las Vegas, Nevada
ID Care
Hillsborough, New Jersey
AXCES Research Group
Santa Fe, New Mexico
New York-Presbyterian Queens
Flushing, New York
Jacobi Medical Center
The Bronx, New York
NC TraCS Institute - CTRC: University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Penn Medicine: Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Philadelphia FIGHT Community Health Centers
Philadelphia, Pennsylvania
Central Texas Clinical Research, LLC
Austin, Texas
AIDS Arms Inc
Dallas, Texas
North Texas Infectious Diseases Consultants, P.A.
Dallas, Texas
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.